https://www.selleckchem.com/pr....oducts/BIX-02189.htm
65; 95% CI 1.23-2.22). Consistent results were observed in other sensitivity analyses. This post-marketing study in a real-world setting suggests that the use of remdesivir is significantly associated with an increased risk of reporting bradycardia and serious bradycardia when compared with the use of with hydroxychloroquine, lopinavir/ritonavir, tocilizumab or glucocorticoids. This result is in line with the pharmacodynamic properties of remdesivir. This post-marketing study in a real-world setting suggests that the use of remdesivir
Like
Comment
Share
